Priorities for research needed to contain the spread of the virus and its vectors will be defined and agreed upon, all with the aim of reducing morbidity and mortality in endemic countries. Improved surveillance and better estimation of disease burden will be examined, along with methods of improving public commitment to the control and eventual elimination of the disease, a major threat to public health around the world.

Major topics will include pathophysiology, diagnosis, clinical management, epidemiological surveillance, laboratory aspects, vector biology, ecology and control, advocacy for social and community commitment, viro-molecular considerations, and vaccine development. Participants are encouraged to submit papers focusing on one or more of these topics, or to form a new topic area if there is sufficient interest.

GenPhar, Inc. is a biopharmaceutical company dedicated to becoming a leader in developing and producing prophylactic and therapeutic vaccines to protect against the world’s most dangerous diseases. To reach its goals, GenPhar will leverage the advantage of its proven safe and effective ProVax and TheraVax vaccine platforms -- unique technology capable of producing multiple vaccine products. GenPhar's products are divided into two main areas: vaccines for biodefense and vaccines for chronic infectious diseases (including HIV, hepatitis B and hepatitis C). These products will have a large scale socio-economic impact and transformative effect on current research and treatments. GenPhar was founded in 1999 and is headquartered in Mount Pleasant, South Carolina.

To learn more about GenPhar and its vaccine programs, please contact us.